Trial of ganglioside GM1 in acute stroke.

GM1 ganglioside therapy in acute ischemic stroke.

Gangliosides (GM1 and AGF2) reduce mortality due to ischemia: protection of membrane function.

As evidenced by their ability to reduce cerebral edema, exogenous ganglioside administration exerts acute effects on CNS injury processes. We report here that ganglioside (GM1 or AGF2) treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery. By comparing the occluded vs. nonoccluded sides ...

Failure of GM1 ganglioside to influence outcome in experimental focal ischemia.

BACKGROUND AND PURPOSE Reports of improved short-term (less than 72 hours) outcome in experimental models of mechanical and ischemic central nervous system injury suggest that exogenous ganglioside administration may confer a protective effect on neural tissue. We studied the effect of the monosialoganglioside GM1 on cerebral infarction and edema in spontaneously hypertensive rats subjected to ...

Effect of GM1 ganglioside after focal cerebral ischemia in halothane-anesthetized cats.

The effect of the ganglioside GM1 was studied in a focal cerebral ischemia model in 30 cats consisting of 2 hours of middle cerebral artery occlusion followed by 4 hours of recirculation. The cerebrocortical electrical activity, extracellular potassium activity, and microcirculation indicated by NAD/NADH fluorescence were measured during occlusion as well as during recirculation in the core of ...

Gangliosides for acute ischemic stroke.

BACKGROUND Gangliosides may have a protective effect on the central and peripheral nervous systems. OBJECTIVES The objective of this review was to assess the effect of exogenous gangliosides in acute ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register (last searched: May 2001) and contacted drug companies and main investigators of included trials. SELEC...